# BIO-106

Source: https://onco.cc/drugs/bio-106/  
OnCo record `bio-106` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BIO-106 is an experimental antibody-drug conjugate from BiOneCure Therapeutics in phase 2 trials, aimed at TROP2.

## Summary

BIO-106 is an antibody-drug conjugate developed by BiOneCure Therapeutics. Its target is TROP2 (the sponsor names Trop-2). The sponsor states: BIO-106 is a novel antibody-drug conjugate targeting the human trophoblast cell surface antigen 2 (Trop-2). ClinicalTrials.gov describes the intervention as: BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05320588, plans to enrol 332 participants with primary completion was scheduled for 2024-04 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: BIO-106 is a novel antibody-drug conjugate targeting the human trophoblast cell surface antigen 2 (Trop-2).

## Sources

- ClinicalTrials.gov: trials of BIO-106: https://clinicaltrials.gov/search?intr=BIO-106

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [A Study in Patients With Advanced Cancers](https://onco.cc/trials/nct05320588/)

---
JSON: https://onco.cc/api/v1/entities/bio-106.json